Cargando…
A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy
A resolutive therapy for muscular dystrophies, a heterogeneous group of genetic diseases leading to muscular degeneration and in the severe forms to death, is still lacking. Since inflammation and defects in nitric oxide generation are recognized key pathogenic events in muscular dystrophy, we have...
Autores principales: | Sciorati, Clara, Miglietta, Daniela, Buono, Roberta, Pisa, Viviana, Cattaneo, Dario, Azzoni, Emanuele, Brunelli, Silvia, Clementi, Emilio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academic Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3134707/ https://www.ncbi.nlm.nih.gov/pubmed/21609764 http://dx.doi.org/10.1016/j.phrs.2011.05.003 |
Ejemplares similares
-
Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy
por: Miglietta, Daniela, et al.
Publicado: (2015) -
Nitric Oxide Sustains Long-Term Skeletal Muscle Regeneration by Regulating Fate of Satellite Cells Via Signaling Pathways Requiring Vangl2 and Cyclic GMP
por: Buono, Roberta, et al.
Publicado: (2012) -
Combined isosorbide dinitrate and ibuprofen as a novel therapy for muscular dystrophies: evidence from Phase I studies in healthy volunteers
por: Cossu, Maria Vittoria, et al.
Publicado: (2014) -
Nitric Oxide (NO) and Duchenne Muscular Dystrophy: NO Way to Go?
por: Timpani, Cara A., et al.
Publicado: (2020) -
Skeletal Muscle Homeostasis in Duchenne Muscular Dystrophy: Modulating Autophagy as a Promising Therapeutic Strategy
por: De Palma, Clara, et al.
Publicado: (2014)